<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044599</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11/24</org_study_id>
    <nct_id>NCT04044599</nct_id>
  </id_info>
  <brief_title>Lactobacillus for Luteal Phase Support</brief_title>
  <official_title>Lactobacillus for Luteal Phase Support to Improve IVF Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effect of vaginal lactobacilli, a regulator of&#xD;
      normal vaginal flora, on embryo implantation success during IVF / ICSI cycle follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urogenital region accounts for 9% of the total human microbiome. The role of vaginal&#xD;
      microbioma in infertility and assisted reproductive technologies has not yet been clarified.&#xD;
      It is thought that microorganisms such as mycoplasma, chlamydia and Neiseria gonorrhea are&#xD;
      associated with infertility, and changes in subclinical microbiota such as bacterial&#xD;
      vaginosis (BV) may be a risk factor for subfertility. The majority of the normal elements of&#xD;
      the vaginal flora are the various Lactobacillus species. Lactobacilli constitute a healthy&#xD;
      environment for the embryo in the pre- and peri-conception period. They are thought to&#xD;
      support implantation not only by their presence but also by the lactic acid, hydrogen&#xD;
      peroxide, bacteriocin and probiotics they produce. Bacterial vaginosis (BV) is the reduction&#xD;
      of lactobacilli in the dominance of the vaginal microbiota and the transition of the&#xD;
      microbial environment to the dominance of Gardnella vaginalis.The two main functions of&#xD;
      lactobacilli in translating the balances in the reproductive system in favor of successful&#xD;
      implantation and pregnancy rates; lactic acid production and H 2 O 2 recovery. It has been&#xD;
      shown that up to 40% of patients undergoing in vitro fertilization (IVF) cycles have abnormal&#xD;
      reproductive tract microbiata. To date, studies on vaginal microbiata and implantation have&#xD;
      been carried out to identify vaginal microbiome by genetic sequencing of the vaginal&#xD;
      specimens. In these studies, endometrial microbiota; When lactobacilli were classified as&#xD;
      dominant (&gt; 90%) and non-lactobacilli were dominant; In the presence of lactobacilli&#xD;
      non-dominant microbiota, decreased implantation, pregnancy and ongoing pregnancy rates and&#xD;
      more negative reproductive results were obtained.&#xD;
&#xD;
      To date, the limited number of studies evaluating the effects of lactobacilli on assisted&#xD;
      reproductive methods success and implantation; vaginal or endometrial lactobacilli burden was&#xD;
      evaluated. Therefore, for the first time in our study; The aim of this study was to evaluate&#xD;
      the effect of vaginal lactobacilli, a regulator of normal vaginal flora, on embryo&#xD;
      implantation success during IVF / ICSI cycle follow-up.The study group will be composed of&#xD;
      patients who will receive 4 vaginal lactobacillus tablet immediately after the OPU&#xD;
      procedure.The ones who will not receive vaginal lactobacillus tablets will compose the&#xD;
      control group.&#xD;
&#xD;
      Patients will be selected from infertile patients that underwent IVF/ICSI protocol. There&#xD;
      will be no change in the routine ovarian stimulation protocols and luteal phase support&#xD;
      treatments that patients should receive routinely. Following ovulation induction with&#xD;
      controlled ovarian stimulation (KOH), which is routinely administered in IVF treatment&#xD;
      cycles, following the collection of oocytes, the luteal phase support is routinely&#xD;
      recommended for the preparation of the endometrium to embryo transfer in artificial,&#xD;
      stimulated cycles on the evening of the same day. If pregnancy occurs, luteal phase support&#xD;
      should be continued for an average of 8 weeks. In fresh embryo transfer cycles, vaginal&#xD;
      progesterone is routinely used for luteal phase support in all patients in our clinic. All&#xD;
      patients will receive the same luteal phase treatment routinely.For the study the patients&#xD;
      who will have day 5 good quality embryo transfer performed will be selected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4 weeks after embryo transfer</time_frame>
    <description>To see the gestational sac</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>To see the fetal cardiac activity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>Ongoing pregnancy after 12 weeks</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gynoflor</intervention_name>
    <description>VAGİNAL GYNOFLOR</description>
    <arm_group_label>Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  having embryo transfer of a day 5 good quality embryo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uterin pathologies&#xD;
&#xD;
          -  Having additional adjuvants for luteal phase support&#xD;
&#xD;
          -  Having day 3 embryo transfer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurkan Uncu, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Uludag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gurkan UNCU, Prof.</last_name>
    <phone>02242952541</phone>
    <email>guncu@gurkanuncu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isil Kasapoglu, Specialist</last_name>
    <phone>02242952542</phone>
    <email>kasapogluisil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uludag University ART Center</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gürkan Uncu, Prof.</last_name>
      <phone>02242952541</phone>
      <email>guncu@gurkanuncu.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>GÜRKAN UNCU,PROF. MD</investigator_full_name>
    <investigator_title>Prof. Dr. Gürkan Uncu</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

